Sign in Sign up for free

Last updated: 6 December 2019 at 1:20pm EST

Lawrence Best Net Worth




The estimated Net Worth of Lawrence C Best is at least $8.06 Million dollars as of 12 June 2014. Mr. Best owns over 9,184 units of Myriad Genetics stock worth over $394,226 and over the last 21 years he sold MYGN stock worth over $7,288,100. In addition, he makes $380,488 as Independent Director at Myriad Genetics.

Mr. Best MYGN stock SEC Form 4 insiders trading

Lawrence has made over 8 trades of the Myriad Genetics stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 9,184 units of MYGN stock worth $229,233 on 12 June 2014.

The largest trade he's ever made was buying 100,000 units of Myriad Genetics stock on 16 June 2006 worth over $4,656,000. On average, Lawrence trades about 11,080 units every 99 days since 2003. As of 12 June 2014 he still owns at least 15,001 units of Myriad Genetics stock.

You can see the complete history of Mr. Best stock trades at the bottom of the page.





Lawrence Best biography

Lawrence C. Best is no longer serves as Independent Director of the Company effective 12/2020. He is the Chairman and Founder of OXO Capital LLC, an investment firm focused on life sciences and therapeutic medical device companies, since 2007. He joined Boston Scientific Corporation in 1992 and served for 15 years as the Executive Vice President-Finance & Administration and Chief Financial Officer. Prior to joining Boston Scientific, Mr. Best was a partner in the accounting firm of Ernst & Young, where he specialized in serving multinational companies in the high technology and life sciences fields. He served a two-year fellowship at the SEC from 1979 to 1981 and a one-year term as a White House-appointed Presidential Exchange Executive in Washington, D.C. He is a founding director of the President’s Council at Massachusetts General Hospital. Within the past five years Mr. Best also has served on the Board of Directors of Haemonetics Corp, Biogen, Inc. and as Executive Chairman of Cardiovalve Ltd., a privately held medical device company based in Tel Aviv, Israel. He received a B.B.A. degree from Kent State University.

What is the salary of Lawrence Best?

As the Independent Director of Myriad Genetics, the total compensation of Lawrence Best at Myriad Genetics is $380,488. There are 13 executives at Myriad Genetics getting paid more, with R. Bryan Riggsbee having the highest compensation of $3,138,980.



How old is Lawrence Best?

Lawrence Best is 70, he's been the Independent Director of Myriad Genetics since 2009. There are 2 older and 24 younger executives at Myriad Genetics. The oldest executive at Myriad Genetics, Inc. is Walter Gilbert, 87, who is the Independent Vice Chairman of the Board.

What's Lawrence Best's mailing address?

Lawrence's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.

Insiders trading at Myriad Genetics

Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum, and Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.



What does Myriad Genetics do?

myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.



What does Myriad Genetics's logo look like?

Myriad Genetics, Inc. logo

Complete history of Mr. Best stock trades at Biogen Inc, Myriad Genetics, and Haemonetics

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
12 Jun 2014 HAE Haemonetics Corp. Lawrence C Best
Director
 Option 9,184 $24.96 $229,233
12 Jun 2014
15,001 ↗
3 May 2013 HAE Haemonetics Corp. Lawrence C Best
Director
 Option 12,000 $26.38 $316,560
3 May 2013
20,352 ↗
4 Feb 2011 HAE Haemonetics Corp. Lawrence C Best
Director
 Option 32,000 $26.07 $834,240
4 Feb 2011
6,896 ↗
18 Feb 2010 HAE Haemonetics Corp. Lawrence C Best
Director
 Sale 50,000 $53.42 $2,671,000
18 Feb 2010
1,008 ↗
16 Feb 2010 HAE Haemonetics Corp. Lawrence C Best
Director
 Sale 50,000 $53.57 $2,678,500
16 Feb 2010
51,008 ↗
16 Jun 2006 HAE Haemonetics Corp. Lawrence C Best
Director
 Buy 100,000 $46.56 $4,656,000
16 Jun 2006
100,000 ↗
22 Aug 2003 HAE Haemonetics Corp. Lawrence C Best
Director
 Buy 100,000 $46.56 $4,656,000
22 Aug 2003
100,000 ↗
30 Nov 2010 MYGN Myriad Genetics, Inc. Lawrence C Best
Director
 Sale 90,000 $21.54 $1,938,600
30 Nov 2010
100,000 ↗


Myriad Genetics executives and stock owners

Myriad Genetics executives and other stock owners filed with the SEC include: